Key insights
- Lantern Pharma's upcoming June webcast on its AI platform, withZeta, could signal a significant shift in market valuation. Investors will be looking for evidence of paying customers, subscription revenue, partnerships, or a potential spin-off, suggesting the AI platform may be the primary value driver rather than the drug pipeline. This could lead to a re-evaluation of the company's stock.
$LTRN What happens in June?
Lantern Pharma has announced a dedicated June webcast focused on withZeta, its AI platform business.
The most important question isn’t about the pipeline.
It’s whether management starts presenting Lantern as more than a biotech company.
Will we hear about:
- Paying customers? • Subscription revenue? • Strategic partnerships? • A spin-off or independent entity for withZeta? • A roadmap to commercialize the platform?
If withZeta is positioned as a standalone business, June could mark the beginning of a major shift in how the market values Lantern.
The drugs may be the proof of concept. The platform may be the real story.
I‘m long LTRN. Do your own DD.